Read by QxMD icon Read


R J Rodgers
The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at
August 26, 2016: Neuroscience and Biobehavioral Reviews
Diana Isaacs, Lalita Prasad-Reddy, Sneha Baxi Srivastava
PURPOSE: Published data on the weight loss effects of glucagon-like peptide 1 (GLP-1) receptor agonists are reviewed, with a focus on data from clinical trials. SUMMARY: Obesity is a significant health problem in the United States (an estimated 69% of U.S. adults are overweight and nearly 35% are obese), and few drugs have proven safety and efficacy as adjuncts to lifestyle modification for weight management. GLP-1 receptor agonists are used for glycemic control in patients with type 2 diabetes and have been studied for their weight loss effects in patients with and without diabetes; these agents produce weight loss benefits through their effects on satiety and gastric emptying...
October 1, 2016: American Journal of Health-system Pharmacy: AJHP
J Suzin Whitten
No abstract text is available yet for this article.
July 15, 2016: American Family Physician
A J Scheen
Liraglutide is an analogue of Glucagon-Like Peptide-1 (GLP-1) already indicated under the trade name of Victoza for the treatment of type 2 diabetes, at usual doses of 1.2 or 1.8 mg as once daily subcutaneous injection. It is henceforth indicated at a dose of 3.0 mg, also as once daily subcutaneous injection, for the treatment of obesity or overweight with comorbidities under the trade name of Saxenda, in combination with diet and exercise. Besides a specific action on the endocrine pancreas, mainly responsible for the antihyperglycaemic effect, liraglutide helps controlling appetite at the hypothamalic level...
May 2016: Revue Médicale de Liège
(no author information available yet)
No abstract text is available yet for this article.
March 15, 2016: JAMA: the Journal of the American Medical Association
(no author information available yet)
No existing weight loss drug has an acceptable harm-benefit balance. Liraglutide, a GLP-1 agonist administered by subcutaneous injection and already authorised in type 2 diabetes, is also approved for use in the European Union by obese patients or overweight individuals with other cardiovascular risk factors. The recommended dose in this setting is 3 mg per day, instead of the dose of 1.2 to 1.8 mg per day used in diabetes. In four randomised, double-blind, placebo-controlled trials, each lasting one year, mean weight loss with liraglutide, beyond the placebo effect, was about 5% among patients initially weighing between 100 and 118 kg...
January 2016: Prescrire International
Olga M Klibanov, Diep Phan, Kelli Ferguson
This article highlights important prescribing information for some drugs that received FDA approval within the past year. These include: atazanavir and cobicistat (Evotaz®), ceftazidime and avibactam (Avycaz®), edoxaban (Savaysa®), ivabradine (Corlanor®), liraglutide (rDNA origin) injection (Saxenda®), perindopril arginine and amlodipine besylate (Prestalia®), and secukinumab (Cosentyx®) subcutaneous injection.
December 12, 2015: Nurse Practitioner
W Scott Butsch
PURPOSE OF REVIEW: Lifestyle modification remains the mainstay of treatment for obesity despite the lack of substantial long-term efficacy. For many who do not respond to lifestyle therapy and are not candidates for weight loss surgery, pharmacotherapy is a viable treatment option. Advances in understanding mechanisms of appetite control, nutrient sensing, and energy expenditure have not only helped shape current drug development but have also changed the way in which antiobesity medications are prescribed...
October 2015: Current Opinion in Endocrinology, Diabetes, and Obesity
Eva Winning Iepsen, Signe Sørensen Torekov, Jens Juul Holst
Subcutaneous liraglutide (Victoza(®), Novo Nordisk) was approved for the treatment of Type 2 diabetes mellitus (T2DM) in Europe in 2009 and in the USA in 2010. In December 2014, liraglutide 3.0 mg was approved by the Food and Drug Administration (FDA) and in March 2015 by the European Medicines Agency (EMA) for the treatment of chronic weight management under the brand name Saxenda(®) Novo Nordisk. Liraglutide causes a glucose-dependent increase in insulin secretion, decreases glucagon secretion and promotes weight loss by inhibiting appetite...
2015: Expert Review of Cardiovascular Therapy
(no author information available yet)
No abstract text is available yet for this article.
June 22, 2015: Medical Letter on Drugs and Therapeutics
Georgios A Christou, Niki Katsiki, Dimitrios N Kiortsis
OBJECTIVE: Liraglutide 3.0 mg daily dose is marketed under the brand name Saxenda and was recently approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) as adjunct to a comprehensive lifestyle intervention to achieve weight loss. DESIGN: Human studies using liraglutide 3.0 mg daily dose were selected through search based on PubMed listings and the Clinical database using the term "liraglutide". RESULTS: During 56 weeks of treatment, liraglutide 3...
2016: Current Vascular Pharmacology
Jennifer N Clements, Kayce M Shealy
OBJECTIVE: To review the efficacy and safety of liraglutide, marketed as Saxenda, a glucagon-like peptide-1 analog for obesity management. DATA SOURCES: A MEDLINE search (1970 to March 2015) was conducted for English-language articles using the terms glucagon-like peptide 1, liraglutide, and obesity. STUDY SELECTION AND DATA EXTRACTION: Published articles pertinent to the efficacy and safety of liraglutide for short- and long-term obesity management among overweight or obese patients and special populations were reviewed and summarized...
August 2015: Annals of Pharmacotherapy
Lesley J Scott
Globally, obesity has reached epidemic proportions and poses an ever increasing burden from a societal and healthpayer perspective. Although lifestyle interventions are fundamental in its management, in the real world setting most obese or overweight adults require adjunctive pharmacotherapy to achieve clinically relevant reductions in bodyweight (i.e. a ≥5 % reduction). Subcutaneous liraglutide (Saxenda(®)) 3 mg once daily is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic bodyweight management in adults with an initial body mass index (BMI) of ≥30 kg/m(2) (obese) or a BMI of ≥27 kg/m(2) (overweight) and at least one bodyweight-related comorbidity [e...
May 2015: Drugs
Ellen E Ladenheim
The prevalence of obesity worldwide has nearly doubled since 1980 with current estimates of 2.1 billion in 2013. Overweight and obesity lead to numerous adverse conditions including type 2 diabetes, cardiovascular disease, stroke, and certain cancers. The worldwide spread of obesity and associated comorbidities not only threatens quality of life but also presents a significant economic burden. While bariatric surgery has proven to be a viable treatment option for the morbidly obese, there is clearly a need for less invasive alternatives...
2015: Drug Design, Development and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"